Array paying next to nothing for Novartis BRAF inhibitor
This article was originally published in Scrip
As its acquisition of GlaxoSmithKline's oncology portfolio draws nearer to closing, Novartis is essentially paying Array BioPharma to take over development and commercialization of the BRAF inhibitor encorafenib (LGX818) just one month after the Swiss big pharma gave back its rights to Array's MEK inhibitor binimetinib under attractive terms.
You may also be interested in...
Array believes that a zero copay offer for patients will help its newly FDA-approved Mektovi/Braftovi combination stand out from the crowd in melanoma and notes that the regimen also has potential in a larger indication – colon cancer.
Shares in Array Biopharma shot up by more than 80% on the release of top-line Phase III data from its COLUMBUS study of encorafenib and binimetinib, but more details are needed to gauge how the combination may fare against Novartis and Roche’s more established combos, and the newer IO therapies.
Public Company Edition: Drug developers continue to take advantage of investors’ preference for biotechnology investments, with CRISPR, Acceleron and BioNTech raising massive sums. The wealth isn’t spreading to everyone, however, as DBV Technologies is restructuring and cutting jobs.